Pharmacological properties
Immunological and biological properties
Respibron is an immunomodulator based on bacterial lysate that increases the body's resistance to infections by increasing the number of serum and secretory antibodies, activating cellular and humoral factors of nonspecific immunity. This leads to a decrease in the frequency and severity of respiratory infections, as well as a decrease in the use of antibiotics.
The technology of mechanical disintegration of microbial cultures makes it possible to isolate native highly immunogenic material from large fragments of the cell walls of microbial cells by removing ballast antigen-inactive and toxic molecules, which allows to induce a high level of production of specific antibodies. Large antigenic structures are well recognized by the immune system, and the structural immutability of the antigenic material, in contrast to widely used methods of chemical lysis of bacteria, allows to form a highly specific response to the most common pathogens of respiratory infections. Respibron has a dual mechanism of action:
activates nonspecific resistance (rapid protection within 2-4 weeks from the start of taking Respibron) due to membrane antigens that are part of the drug, by activating dendritic cells, neutrophils, macrophages and NK cells; induction of phagocytosis and cell lysis by stimulating adhesion of macrophages to bacteria; activates specific immunity (long-term protection for several years) by increasing the level of interleukin (IL-2) production, specific serum IgA, G, M and sIgA, activation of effector CD4 and CD8 T-lymphocytes, B-lymphocytes.
The immunostimulating properties of Respibron are due to:
in vitro: increased production of IL-12, IL-2, IL-10 and IFNg (CD4 + Th type 1), expression of the receptor for IL-2 in B lymphocytes, CD4 + and CD8 + in T lymphocytes, the number of CD4 + and CD8 + effector T cells; in vivo: increased activity of IgM of memory B lymphocytes (CD24 +, CD27 +), expression of the receptor for IL-2 in B lymphocytes and CD4 + and CD8 + in T lymphocytes; increased level of secretory IgA on the mucous membranes of the respiratory tract, which provides inhibition of attachment of viral and bacterial cells, neutralization of enzymes and toxins of infectious pathogens, which are especially important in providing Respibron with its prophylactic properties against pathogens of acute, chronic and recurrent infections, as well as diseases of the upper and lower respiratory tract.
Respibron is well absorbed in the oral mucosa, which makes it convenient to use.
Indication
Acute, subacute, recurrent and chronic infections of the upper respiratory tract (ARVI, influenza, rhinitis, including allergic, sinusitis, laryngitis, tonsillitis, pharyngitis, nasopharyngitis, tonsillitis, epiglottitis); acute, subacute, recurrent or chronic infections and diseases of the lower respiratory tract, including obstructive (tracheitis, tracheobronchitis, bronchitis, bronchiectasis, COPD).
Due to its immunomodulatory effect, Respibron reduces the number and intensity of acute respiratory diseases in children who are often and for a long time ill, as well as the number of exacerbations of COPD per year and the severity of their course. The drug is used to treat infections resistant to antibiotic therapy, as well as complications of bacterial and viral infections. Respibron can be used in combination with other drugs (antibiotics and mucolytics).
Application
For oral use in adults and children aged 2 years and over.
Treatment of acute processes: dissolve 1 tablet under the tongue for 1-2 minutes once a day (it is necessary to refrain from eating for at least 30 minutes). Take daily until symptoms disappear for at least 10 days. The course of treatment involves taking 10 tablets.
Preventive treatment: dissolve 1 tablet under the tongue for 1-2 minutes once a day. The course of treatment is 10 days. After a 20-day break, repeat the 10-day course of taking the drug. The full course of treatment, in which the maximum immunotherapeutic effect is achieved, is 3 months. During the full course of treatment, it is necessary to take 30 tablets of Respibron. That is, Respibron is taken in 3 ten-day courses for 3 months with two 20-day breaks between them.
For younger children, it is recommended to first crush the tablet, moisten it with boiled water at room temperature, and place the resulting mixture in the mouth.
Contraindication
Hypersensitivity to the components of the drug.
Side effects
Rarely - the occurrence of skin allergic reactions (itching, irritation).
Special instructions
Pregnancy and lactation: No toxic effects of respibron have been observed in animals, however, it is recommended to avoid using the drug during the first 3 months of confirmed or suspected pregnancy.
Ability to influence the reaction rate when driving vehicles or working with other mechanisms. The drug does not affect the ability to drive vehicles and work with other mechanisms.
Interactions
No interactions with other drugs, including antibiotics, were observed.
Overdose
No cases of overdose have been reported.
Storage conditions
At a temperature not exceeding 25 °C.
